• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A journey through clinic and research
I started to study Medicine at the University of Genoa, Italy more than 20 years ago and I now realize that I was quite far from understanding what ‘Medicine’ really means. After weeks and weeks spent on books during the first year, I understood that becoming a MD not only requires the willingness to help people with health problems, but also strong motivation and dedication to learn a huge amount of notions. In Italy, as it is the case for several other countries, the University courses last 6 years, during which the MD student is fully engaged by individual study, lessons and seminars, exercises, and internships. Wit...
Source: European Heart Journal - March 29, 2021 Category: Cardiology Source Type: research

Developing the right pathway
The pathway foundation: guidelines The available NICE guidelines on ICM provide a solid basis for developing a pathway for investigation of patients with cryptogenic stroke or ESUS (NICE Guideline DG41, 2020). Ensuring specialists are broadly aware of these guidelines is important, particularly across both stroke and cardiology specialties. ...
Source: Radcliffe Cardiology - March 22, 2021 Category: Cardiology Authors: c242508f1d9059bc0f2aa9bdd5421ba2 Source Type: research

103 How is our local AF management? The management of atrial fibrillation (af) in coventry and rugby clinical commissioning group (ccg), england compared to national data and nice (national institute for clinical excellence) 2014
Background: AF is the most common cardiac arrhythmia affecting 2% in the UK.AF carriers 5 fold risk of stroke, with increased stroke mortality, morbidity& longer hospital stay.CHADSVAs guides anti-coagulation ( ≥1 anti-coagulate)Risk factor modification reduces AF reoccurrenceNurse led clinics reduce AF related stroke risk, improve AF management, risk factor reduction whilst providing safe anticoagulation.
Source: Europace - October 5, 2017 Category: Cardiology Source Type: research

115 Anticoagulation in atrial fibrillation – a single-centre audit on patient education, stroke and bleeding risk assessments and use of direct oral anticoagulants (DOACs)
Objective: To assess adherence to the National Institute of Health and Care Excellence (NICE) guidelines on management of atrial fibrillation in adults, specifically the provision of a personalised package of care and information to patients, and stroke and bleeding risk assessments. To assess the frequency of use of DOACs as the anticoagulant of choice.
Source: Europace - October 5, 2017 Category: Cardiology Source Type: research

124 GP-led anticoagulation counselling for non-valvular atrial fibrillation (AF) in the community is neither comprehensive nor accurate: Results from a service improvement project.
Background: Stroke risk in NVAF can be reduced significantly by anticoagulation with either warfarin or the non- vitamin K antagonist (NOACs). NICE recommendations state that NOACs are as efficacious but also associated with significantly less intracranial bleeding compared to Warfarin and in this sense are safer than warfarin. Additionally NOACs do not require regular monitoring of their anticoagulant effects and therefore offer convenience to the patient. However they are not as tried and tested as warfarin and at the time of our study, did not have an available agent to reverse their effects in the event of a bleeding c...
Source: Europace - October 5, 2017 Category: Cardiology Source Type: research

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
This report ends with a list of priorities for research in AF patients.
Source: Europace - February 3, 2016 Category: Cardiology Authors: Kirchhof, P., Breithardt, G., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H., Calvert, M., Christoffels, V., Crijns, H., Dobrev, D., Ellinor, P., Fabritz, L., Fetsch, T., Freedman, S. B., Tags: EHRA CONSENSUS STATEMENT Source Type: research

Nov 20 Cardiology NewsNov 20 Cardiology News
Watchman CMS proposal, NICE proposal on evolocumab in the UK, cryptogenic stroke, disclosing genetic risk of future CHD, and coffee intake are the topics for this week's podcast from Dr John Mandrola. theheart.org on Medscape
Source: Medscape Cardiology Headlines - November 20, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Resistant hypertension: resistance to treatment or resistance to taking treatment?
The treatment of hypertension has been a therapeutic success. A generation or more of effective drugs deserves considerable credit for their contribution to the substantial decline in age-related incidence of stroke, ischaemic heart disease and heart failure. And because almost all the drugs are long-since off patent, the cost of success comes cheaply. Indeed, National Institute of Health and Care Excellence (NICE) has branded treatment of hypertension as not only cost effective but cost saving.1 Yet not all patients achieve their blood pressure target and are labelled as ‘resistant hypertension’. A contentious...
Source: Heart - May 8, 2014 Category: Cardiology Authors: Brown, M. J. Tags: Drugs: cardiovascular system, Hypertension, Interventional cardiology, Epidemiology Editorials Source Type: research

NICE costing statement for its guidance on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: News NICE has published a costing statement to accompany its guidance on the use of apixaban for preventing stroke and systemic embolism in nonvalvular atrial fibrillation (TA 275).   The statement notes that "Apixaban provides an alternative treatment option at a comparable cost and therefore it is anticipated that there will not be a significant cost impact as a result of implementing this guidance."
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: Evidence > Guidelines NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:   . prior stroke or transient ischaemic attack . age 75 years or older . hypertension . diabetes mellitus . symptomatic heart failure.   NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

InFocus: Plans to Streamline Stroke Research in the Works
HONOLULU (MedPage Today) -- Wouldn't it be nice if a clinical trial took only months to initiate rather than years? The NIH thinks so too and has a plan to make that dream come true, deputy director Walter Koroshetz, MD, said in this exclusive InFocus interview.
Source: MedPage Today Cardiovascular - February 11, 2013 Category: Cardiology Source Type: news

NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE Area: News In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).   The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news

NHS Evidence expert commentary: Benefits of drug therapy are unclear for mild hypertension
Source: NHS Evidence Area: News The January edition of 'Eyes on Evidence', the free monthly e-bulletin from NHS Evidence covering major new published evidence as it emerges with an explanation about what it means for current practice, includes an expert commentary on new data from a Cochrane review that aimed to quantify the effects of antihypertensive drug therapy versus no treatment on mortality and morbidity in adults with mild hypertension and no evidence of cardiovascular disease. It included four RCTs with 8912 participants. The review concluded that, compared with placebo, antihypertensive treatment does not reduce...
Source: NeLM - Cardiovascular Medicine - January 10, 2013 Category: Cardiology Source Type: news